Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Receivables - Other (2017 - 2025)

Historic Receivables - Other for Cytosorbents (CTSO) over the last 9 years, with Q3 2025 value amounting to $6.0 million.

  • Cytosorbents' Receivables - Other rose 2377.11% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year increase of 2377.11%. This contributed to the annual value of $4.4 million for FY2024, which is 1509.85% up from last year.
  • Cytosorbents' Receivables - Other amounted to $6.0 million in Q3 2025, which was up 2377.11% from $6.6 million recorded in Q2 2025.
  • Cytosorbents' 5-year Receivables - Other high stood at $6.6 million for Q2 2025, and its period low was $2.8 million during Q1 2021.
  • Moreover, its 5-year median value for Receivables - Other was $4.3 million (2022), whereas its average is $4.4 million.
  • The largest annual percentage gain for Cytosorbents' Receivables - Other in the last 5 years was 6233.87% (2021), contrasted with its biggest fall of 13.44% (2021).
  • Cytosorbents' Receivables - Other (Quarter) stood at $3.0 million in 2021, then grew by 27.39% to $3.8 million in 2022, then increased by 0.62% to $3.8 million in 2023, then rose by 15.1% to $4.4 million in 2024, then skyrocketed by 35.46% to $6.0 million in 2025.
  • Its Receivables - Other stands at $6.0 million for Q3 2025, versus $6.6 million for Q2 2025 and $5.9 million for Q1 2025.